Table 2.
Non-inferiority assessment of Hb changes from baseline at Week 7 between FC groups and SF group (mITT population)
| Visit | Step | Group | n | Change in Hb concentration from baseline | Difference vs. SF group | ||
|---|---|---|---|---|---|---|---|
| LSM | 95% CI | LSM | 95% CI | ||||
| Week 7 | Step 1 | FC-high | 171 | 3.29 | 3.15–3.42 | 0.18 | − 0.01 to 0.37 |
| SF | 169 | 3.11 | 2.97–3.24 | – | – | ||
| Step 2 | FC-low | 173 | 2.75 | 2.62–2.88 | − 0.36 | − 0.55 to − 0.18 | |
| SF | 169 | 3.11 | 2.98–3.24 | – | – | ||
Hb hemoglobin, mITT modified intention-to-treat, LSM least-squares mean, CI confidence interval, FC-low group ferric citrate hydrate at 500 mg/day, FC-high group ferric citrate hydrate at 1000 mg/day, SF group sodium ferrous citrate at 100 mg/day